Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Plunkett Research, Ltd.
$99.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bristol-Myers Squibb Co Drug Shrinks Melanoma In 31% Of Trial Patients-Reuters


Monday, 3 Jun 2013 07:33am EDT 

Reuters reported that Bristol-Myers Squibb Co's experimental drug shrank tumors in 31% of patients with advanced melanoma, the deadliest form of skin cancer, according to results from an early-stage trial. The drug, nivolumab, is the most advanced in a new class of immunotherapies designed to work by disabling a brake on the immune system's ability to attack cancer cells. An existing immunotherapy drug, Bristol's Yervoy, which works by disrupting a different cell receptor, has been shown to be effective in up to 10% of people with advanced melanoma. 

Company Quote

49.39
-0.07 -0.14%
4:01pm EDT